Wednesday, July 31, 2024 CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients. This trial is being done to answer the following question: Can survival be improved in your type of brain cancer by using personalized therapy based on changes in the DNA of your tumour? A pre-study screening will test a sample of your tumour tissue for biomarkers to see if you can participate in the study."This is an exciting opportunity for us to test new treatments for patients with brain tumours. In particular this disease affects young adults by substantially reducing their survival and quality of life, so any improvements we may see can be profoundly impactful," says study Principal Investigator Dr Marshall Pitz, a Medical Oncologist at CancerCare Manitoba and Associate Professor of Medicine, University of Manitoba. The purpose of this study is to compare the effects on you and your brain cancer with new and adapted drugs compared to commonly used drugs to treat this disease. "This is the trial I have been hoping for since I was diagnosed with Brain Cancer nearly 11 years ago," says CCTG patient representative Catherine Wreford. "Too many people have been lost to re-occurrence and this is a step in the right direction. Research works and now we can move forward to test new treatments."Brain cancers that are classified as grade 2 or 3 gliomas are incurable and when they recur after treatment, the lack of effective therapies for these hard-to-treat cancers leads to very poor outcomes. With the 5-year survival rate after recurrence approaching 0%, there is an urgent need for new, effective therapies. Currently, there are no clinical trials in Canada testing new and promising treatments at the time of recurrence. Joining the international study was made possible by funding from the CCS Breakthrough Team Grants: Transforming Low-Survival Cancers.For more information, please visit the CE9 patient information page For trial specific information please visit the CCTG CE9 members page
